Detection of low-frequent mitochondrial DNA variants using SMRT sequencing
|
|
- Coral Adams
- 5 years ago
- Views:
Transcription
1 Detection of low-frequent mitochondrial DNA variants using SMRT sequencing Marjolein J.A. Weerts SMRT Leiden 2018 June 13
2 Content Mitochondrial DNA & liquid biopsy in oncology Pitfalls when studying human mitochondrial DNA Approach to detect low-frequent mitochondrial DNA variants using SMRT sequencing Application in a pilot study 2
3 Human mitochondrial DNA Inheritance Structure Nuclear DNA Maternal & Paternal Double stranded lineair Mitochondrial DNA Maternal Double stranded circular Size 3.1 Gb 16.6 kb Cellular content Copies/cell Two* Hundreds to Thousands Gene density ~ 1 / 120 kb ~ 1 / 0.45 kb Mutation rate ~10-fold higher * With the exception of aneuploid tumor cells and germ cells 1
4 Liquid biopsy in oncology Less invasive than a regular biopsy! Blood-circulating cell-free DNA (cfdna) Released by normal as well as tumor cells Genetic information on the patient s cancer (primary tumor ánd metastases) 3 JCO 32(6): , 2014
5 Studying human mtdna in cancer HYPOTHESIS The high mtdna copy number per cell as well as the high mtdna mutation rate make it worthwhile to explore the potential of tumorspecific cf-mtdna variants as cancer marker in the blood of cancer patients 4
6 Studying human mtdna in cancer HYPOTHESIS The high mtdna copy number per cell as well as the high mtdna mutation rate make it worthwhile to explore the potential of tumorspecific cf-mtdna variants as cancer marker in the blood of cancer patients AIMS Detection of low-frequent mtdna variants Highly mtdna-specific detection of mtdna variants 4
7 Pitfalls when studying human mtdna High mutation rate Heteroplasmy Nuclear insertions of mitochondrial origin: NUMTs 5
8 Pitfalls when studying human mtdna High mutation rate Several orders of magnitude higher than that of ndna Nearly 10,000 variable positions reported in databases (e.g. mitomap, mtdb) 6
9 Pitfalls when studying human mtdna Heteroplasmy Genetically different mtdna molecules within a single cell Heteroplasmy patterns differ between tissues within an individual 7
10 Pitfalls when studying human mtdna Nuclear insertions of mitochondrial origin: NUMTs Each 175 bp mtdna segment: ~9.5 NUMT copies Cancer cells contain somatic NUMT insertion events NUMT similarity to mtdna interferes with variant detection 9
11 Studying human mtdna in cancer HYPOTHESIS The high mtdna copy number per cell as well as the high mtdna mutation rate make it worthwhile to explore the potential of tumorspecific cf-mtdna variants as cancer marker in the blood of cancer patients AIMS Detection of low-frequent mtdna variants Highly mtdna-specific detection of mtdna variants 10
12 Highly mtdna-specific detection of mtdna variants Minimize the interference of NUMTs: pure mtdna sample (devoid of nuclear DNA) sequence large fragments SMRT sequencing (~80 of human NUMTs are < 500 bp mtdna segments) 11 MJA Weerts et al., Scientific Reports 2018; 8:2261
13 SMRT sequencing approach for mtdna Amplification of mtdna (15-18 PCR cycles) 9x bp amplicons covering the entire mtdna Purify & pool amplicons (equimolar) per sample Barcode each sample (5 PCR cycles), purify & pool samples Generate SMRTbell library 5 Sequencing on RSII or Sequel 12 MJA Weerts et al., Scientific Reports 2018; 8:2261
14 SMRT sequencing approach for mtdna Amplification of mtdna (15-18 PCR cycles) 9x bp amplicons covering the entire mtdna Purify & pool amplicons (equimolar) per sample Barcode each sample (5 PCR cycles), purify & pool samples Generate SMRTbell library 5 Sequencing on RSII or Sequel 12 MJA Weerts et al., Scientific Reports 2018; 8:2261
15 SMRT sequencing approach for mtdna Amplification of mtdna (15-18 PCR cycles) 9x bp amplicons covering the entire mtdna Purify & pool amplicons (equimolar) per sample Barcode each sample (5 PCR cycles), purify & pool samples Generate SMRTbell library 5 Sequencing on RSII or Sequel 12 MJA Weerts et al., Scientific Reports 2018; 8:2261
16 SMRT sequencing approach for mtdna Amplification of mtdna (15-18 PCR cycles) 9x bp amplicons covering the entire mtdna Purify & pool amplicons (equimolar) per sample Barcode each sample (5 PCR cycles), purify & pool samples Generate SMRTbell library 5 Sequencing on RSII or Sequel 12 MJA Weerts et al., Scientific Reports 2018; 8:2261
17 SMRT sequencing approach for mtdna Amplification of mtdna (15-18 PCR cycles) 9x bp amplicons covering the entire mtdna Purify & pool amplicons (equimolar) per sample Barcode each sample (5 PCR cycles), purify & pool samples Generate SMRTbell library 5 Sequencing on RSII or Sequel 12 MJA Weerts et al., Scientific Reports 2018; 8:2261
18 SMRT sequencing approach for mtdna Generate circular consensus reads (CCS2 algorithm) Attribute reads using sample-specific barcode (TSSV) Select highly accurate CCS reads (QV>=99, >= 5 passes) Trim reads (Cutadapt) and align to extended version or rcrs (BWA-MEM) Call positions alternative to the reference sequence in pileup (Rsamtools, min_nucleotide_depth=5) 13 MJA Weerts et al., Scientific Reports 2018; 8:2261
19 SMRT sequencing approach for mtdna Generate circular consensus reads (CCS2 algorithm) Attribute reads using sample-specific barcode (TSSV) Select highly accurate CCS reads (QV>=99, >= 5 passes) Trim reads (Cutadapt) and align to extended version or rcrs (BWA-MEM) Call positions alternative to the reference sequence in pileup (Rsamtools, min_nucleotide_depth=5) 13 MJA Weerts et al., Scientific Reports 2018; 8:2261
20 SMRT sequencing approach for mtdna Generate circular consensus reads (CCS2 algorithm) Attribute reads using sample-specific barcode (TSSV) Select highly accurate CCS reads (QV>=99, >= 5 passes) Trim reads (Cutadapt) and align to extended version or rcrs (BWA-MEM) Call positions alternative to the reference sequence in pileup (Rsamtools, min_nucleotide_depth=5) 13 MJA Weerts et al., Scientific Reports 2018; 8:2261
21 SMRT sequencing approach for mtdna 6 7 Generate circular consensus reads (CCS2 algorithm) Attribute reads using sample-specific barcode (TSSV) Select highly accurate CCS reads (QV>=99, >= 5 passes) Trim reads (Cutadapt) and align to extended version or rcrs (BWA-MEM) Call positions alternative to the reference sequence in pileup (Rsamtools, min_nucleotide_depth=5) compensate for mapping bias due to circularity of the mitochondrial genome 13 MJA Weerts et al., Scientific Reports 2018; 8:2261
22 SMRT sequencing approach for mtdna Generate circular consensus reads (CCS2 algorithm) Attribute reads using sample-specific barcode (TSSV) Select highly accurate CCS reads (QV>=99, >= 5 passes) Trim reads (Cutadapt) and align to extended version or rcrs (BWA-MEM) Call positions alternative to the reference sequence in pileup (Rsamtools, min_nucleotide_depth=5) 13 MJA Weerts et al., Scientific Reports 2018; 8:2261
23 Detection of low-frequent mtdna variants Determine detection limits empirically: mixtures of the cell lines containing different mtdna variants 14 MJA Weerts et al., Scientific Reports 2018; 8:2261
24 Detection of low-frequent mtdna variants Determine detection limits empirically: mixtures of the cell lines containing different mtdna variants Allele frequency Digital PCR 0/2 0/2 1/2 1/2 2/2 2/2 UltraSEEK 0/7 0/7 0/7 2/7 7/7 7/7 SMRT seq 0/23 0/23 0/23 21/23 23/23 23/23 positions 14 MJA Weerts et al., Scientific Reports 2018; 8:2261
25 Studying human mtdna in cancer HYPOTHESIS The high mtdna copy number per cell as well as the high mtdna mutation rate make it worthwhile to explore the potential of tumorspecific cf-mtdna variants as cancer marker in the blood of cancer patients 10
26 Tumor-specific cf-mtdna variants as cancer marker in the blood of cancer patients? Pilot study: SMRT sequence the entire mtdna of eight cancer patients Tumor, matched normal (tissue of origin!) and cfdna 15 MJA Weerts et al., Neoplasia. 2018; 20(7):
27 Tumor-specific cf-mtdna variants as cancer marker in the blood of cancer patients? Patient 1 Primary breast cancer (2 cm) with lymph nodes involved Neoadjuvant endocrine therapy Surgery, radiation Prolonged endocrine therapy Disease recurrence after 4 months (bone, lung and liver metastases) Second-line endocrine therapy Disease progression Chemotherapy 16 MJA Weerts et al., Neoplasia. 2018; 20(7):
28 Tumor-specific cf-mtdna variants as cancer marker in the blood of cancer patients? Patient 1 Primary breast cancer (2 cm) with lymph nodes involved Neoadjuvant endocrine therapy Surgery, radiation Prolonged endocrine therapy Disease recurrence after 4 months (bone, lung and liver metastases) Second-line endocrine therapy Disease progression Chemotherapy cfdna Primary tumor Normal mammary cfdna 16 MJA Weerts et al., Neoplasia. 2018; 20(7):
29 Tumor-specific cf-mtdna variants as cancer marker in the blood of cancer patients? Patient G>A 5351 A>G 7368 T>C 664 G>A 6255 G>A G>A T>C Primary tumor a Primary tumor b Mammary tissue a Mammary tissue b cfdna (pre surgery) cfdna (post chemo) MJA Weerts et al., Neoplasia. 2018; 20(7):
30 Tumor-specific cf-mtdna variants as cancer marker in the blood of cancer patients? Patient 1 Primary breast cancer (2 cm) with lymph nodes involved cfdna cfdna Neoadjuvant endocrine therapy Surgery, radiation Prolonged endocrine therapy Disease recurrence after 4 months (bone, lung and liver metastases) Second-line endocrine therapy Disease progression Chemotherapy cfdna Primary tumor Normal mammary cfdna cfdna 18 MJA Weerts et al., Neoplasia. 2018; 20(7):
31 Tumor-specific cf-mtdna variants as cancer marker in the blood of cancer patients? Patient G>A 5351 A>G 7368 T>C 664 G>A 6255 G>A G>A T>C Primary tumor a Primary tumor b Mammary tissue a Mammary tissue b cfdna (pre surgery) cfdna (pre 2nd line) na na na na na cfdna (pre chemo) na na na na na cfdna (post chemo) na na na 0 0 na na cfdna (post chemo) MJA Weerts et al., Neoplasia. 2018; 20(7):
32 Tumor-specific cf-mtdna variants as cancer marker in the blood of cancer patients? Patient 2 Colorectal cancer with synchronous hepatic metastases Surgery 20 MJA Weerts et al., Neoplasia. 2018; 20(7):
33 Tumor-specific cf-mtdna variants as cancer marker in the blood of cancer patients? Patient 2 Colorectal cancer with synchronous hepatic metastases cfdna Surgery Primary tumor Normal colon Metastasis 1 Normal liver Metastasis 2 20 MJA Weerts et al., Neoplasia. 2018; 20(7):
34 Tumor-specific cf-mtdna variants as cancer marker in the blood of cancer patients? Patient G>A T>C C>T G>A 66 G>T 152 T>C 189 A>G C>T C>T 1924 T>C 2305 T>C 4048 G>A T>C 60 T>C 72 T>C Primary tumor Metastasis Metastasis Colon tissue Liver tissue cfdna MJA Weerts et al., Neoplasia. 2018; 20(7):
35 Tumor-specific cf-mtdna variants as cancer marker in the blood of cancer patients? Patient G>A T>C C>T G>A 66 G>T 152 T>C 189 A>G C>T C>T 1924 T>C 2305 T>C 4048 G>A T>C 60 T>C 72 T>C Primary tumor Metastasis Metastasis Colon tissue Liver tissue cfdna MJA Weerts et al., Neoplasia. 2018; 20(7):
36 Studying human mtdna in cancer HYPOTHESIS The high mtdna copy number per cell as well as the high mtdna mutation rate make it worthwhile to explore the potential of tumorspecific cf-mtdna variants as cancer marker in the blood of cancer patients 22
37 Studying human mtdna in cancer HYPOTHESIS The high mtdna copy number per cell as well as the high mtdna mutation rate make it worthwhile to explore the potential of tumorspecific cf-mtdna variants as cancer marker in the blood of cancer patients CONCLUSIONS SMRT sequencing suitable for low-frequent mtdna single-nucleotide variant detection. Tumor-specific mtdna variants rarely detected as cfdna. 22
38 Acknowledgements Erasmus MC Medical Oncology John Foekens John Martens Stefan Sleijfer LUMC Leiden Genome Technology Center Rolf Vossen Yahya Anvar contact: Philips Research Precision and Decentralized Diagnostics Dianne van Strijp Pieter-Jan van der Zaag Eveline den Biezen Timmermans Anja van de Stolpe These results have been published Weerts et al., Scientific Reports 2018; 8:2261 Weerts et al., Neoplasia. 2018; 20(7):
LEIDEN, THE NETHERLANDS
Full-length CYP2D6 diplotyping for better drug dosage and response management Henk Buermans, PhD Leiden University Medical Center Human Genetics, LGTC LEIDEN, THE NETHERLANDS CYP2D6 Function Metabolism
More informationAVENIO ctdna Analysis Kits The complete NGS liquid biopsy solution EMPOWER YOUR LAB
Analysis Kits The complete NGS liquid biopsy solution EMPOWER YOUR LAB Analysis Kits Next-generation performance in liquid biopsies 2 Accelerating clinical research From liquid biopsy to next-generation
More informationNext Generation Cancer Diagnostics For First Time Right Therapy Choice. Anja van de Stolpe
Next Generation Cancer Diagnostics For First Time Right Therapy Choice Anja van de Stolpe Paradigm shift in cancer treatment towards personalized treatment Chemotherapy for all therapy targeting cancer
More informationCRISPR/Cas9 Enrichment and Long-read WGS for Structural Variant Discovery
CRISPR/Cas9 Enrichment and Long-read WGS for Structural Variant Discovery PacBio CoLab Session October 20, 2017 For Research Use Only. Not for use in diagnostics procedures. Copyright 2017 by Pacific Biosciences
More informationAVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits
AVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits Accelerating clinical research Next-generation sequencing (NGS) has the ability to interrogate many different genes and detect
More informationIso-Seq Method Updates and Target Enrichment Without Amplification for SMRT Sequencing
Iso-Seq Method Updates and Target Enrichment Without Amplification for SMRT Sequencing PacBio Americas User Group Meeting Sample Prep Workshop June.27.2017 Tyson Clark, Ph.D. For Research Use Only. Not
More informationMutation Detection and CNV Analysis for Illumina Sequencing data from HaloPlex Target Enrichment Panels using NextGENe Software for Clinical Research
Mutation Detection and CNV Analysis for Illumina Sequencing data from HaloPlex Target Enrichment Panels using NextGENe Software for Clinical Research Application Note Authors John McGuigan, Megan Manion,
More informationSupplementary Figure 1. Schematic diagram of o2n-seq. Double-stranded DNA was sheared, end-repaired, and underwent A-tailing by standard protocols.
Supplementary Figure 1. Schematic diagram of o2n-seq. Double-stranded DNA was sheared, end-repaired, and underwent A-tailing by standard protocols. A-tailed DNA was ligated to T-tailed dutp adapters, circularized
More informationThe feasibility of circulating tumour DNA as an alternative to biopsy for mutational characterization in Stage III melanoma patients
The feasibility of circulating tumour DNA as an alternative to biopsy for mutational characterization in Stage III melanoma patients ASSC Scientific Meeting 13 th October 2016 Prof Andrew Barbour UQ SOM
More informationBreast and ovarian cancer in Serbia: the importance of mutation detection in hereditary predisposition genes using NGS
Breast and ovarian cancer in Serbia: the importance of mutation detection in hereditary predisposition genes using NGS dr sc. Ana Krivokuća Laboratory for molecular genetics Institute for Oncology and
More informationCell-free tumor DNA for cancer monitoring
Learning objectives Cell-free tumor DNA for cancer monitoring Christina Lockwood, PhD, DABCC, DABMGG Department of Laboratory Medicine 1. Define circulating, cell-free tumor DNA (ctdna) 2. Understand the
More informationUMC- Maastricht. UMC- Groningen Erasmus MC VUMC TOTAL. NKI UMC-Utrecht Leiden UMC. 245,000-Linn, PKAinduced. of ERa at serine 305 and
NKI UMC-Utrecht Leiden UMC UMC- Maastricht UMC- Groningen Erasmus MC VUMC TOTAL 224,000-Linn, PKAinduced high PAK1 levels is 224,000-van Diest, to tamoxifen in ER-positive in 2007 TOTAL 224,000 224,000
More informationAn innovative multi-dimensional NGS approach to understanding the tumor microenvironment and evolution
An innovative multi-dimensional NGS approach to understanding the tumor microenvironment and evolution James H. Godsey, Ph.D. Vice President, Research & Development Clinical Sequencing Division (CSD) Life
More informationChapter 1 : Genetics 101
Chapter 1 : Genetics 101 Understanding the underlying concepts of human genetics and the role of genes, behavior, and the environment will be important to appropriately collecting and applying genetic
More informationValidation of QClamp as Next Generation Liquid Biopsy Technique for Colorectal Cancer He James Zhu M.D. Ph.D
Validation of QClamp as Next Generation Liquid Biopsy Technique for Colorectal Cancer He James Zhu M.D. Ph.D Department of Radiation Oncology University of Florida College of Medicine Outline Objective
More informationExosome DNA Extraction Kits
Exosome DNA Extraction Kits Summary Section 5 Introduction 40 EXO-DNAc 41 EXO-DNA 43 Introduction Genomic DNA Extractiom Kits Ordering informations Products can be purchased directly in our on-line shop:
More informationCTC in clinical studies: Latest reports on GI cancers
CTC in clinical studies: Latest reports on GI cancers François-Clément Bidard, MD PhD GI cancers are characterized by Multimodal treatment strategies Treatments are adapted to tumor burden & prognosis
More informationDisclosure. Summary. Circulating DNA and NGS technology 3/27/2017. Disclosure of Relevant Financial Relationships. JS Reis-Filho, MD, PhD, FRCPath
Circulating DNA and NGS technology JS Reis-Filho, MD, PhD, FRCPath Director of Experimental Pathology, Department of Pathology Affiliate Member, Human Oncology and Pathogenesis Program Disclosure of Relevant
More informationDNA Methylation of Tumor Suppressor and Metastasis Suppressor Genes in Circulating Tumor Cells and corresponding Circulating Tumor DNA
DNA Methylation of Tumor Suppressor and Metastasis Suppressor Genes in Circulating Tumor Cells and corresponding Circulating Tumor DNA Maria Chimonidou 1, Areti Strati 1, Nikos Malamos 2, Vasilis Georgoulias
More informationAnalysis of Massively Parallel Sequencing Data Application of Illumina Sequencing to the Genetics of Human Cancers
Analysis of Massively Parallel Sequencing Data Application of Illumina Sequencing to the Genetics of Human Cancers Gordon Blackshields Senior Bioinformatician Source BioScience 1 To Cancer Genetics Studies
More informationBinding Calculator Parameters
Binding Calculator Parameters Quick Reference Card The Binding Calculator assists in sample preparation by providing instructions for primer annealing, polymerase binding and sample loading based on the
More informationLa biopsia liquida. Aldo Scarpa. Anatomia Patologica e ARC-NET Centro di Ricerca Applicata sul Cancro
La biopsia liquida Aldo Scarpa Anatomia Patologica e ARC-NET Centro di Ricerca Applicata sul Cancro Azienda Ospedaliera Universitaria Integrata di Verona Obstacles to precision oncology Genomic heterogeneity
More informationNGS in tissue and liquid biopsy
NGS in tissue and liquid biopsy Ana Vivancos, PhD Referencias So, why NGS in the clinics? 2000 Sanger Sequencing (1977-) 2016 NGS (2006-) ABIPrism (Applied Biosystems) Up to 2304 per day (96 sequences
More informationConverting the Hype into Reality: Realizing the Potential of Cell-Free DNA
Converting the Hype into Reality: Realizing the Potential of Cell-Free DNA Lucy Xu, Ph.D. Associate Director Clinical Biomarker Research Eisai Inc. Woodcliff Lake, NJ Precision LBx Summit San Diego, CA
More informationSingle-strand DNA library preparation improves sequencing of formalin-fixed and paraffin-embedded (FFPE) cancer DNA
www.impactjournals.com/oncotarget/ Oncotarget, Supplementary Materials 2016 Single-strand DNA library preparation improves sequencing of formalin-fixed and paraffin-embedded (FFPE) DNA Supplementary Materials
More informationUsing the Bravo Liquid-Handling System for Next Generation Sequencing Sample Prep
Using the Bravo Liquid-Handling System for Next Generation Sequencing Sample Prep Tom Walsh, PhD Division of Medical Genetics University of Washington Next generation sequencing Sanger sequencing gold
More informationA complete next-generation sequencing workfl ow for circulating cell-free DNA isolation and analysis
APPLICATION NOTE Cell-Free DNA Isolation Kit A complete next-generation sequencing workfl ow for circulating cell-free DNA isolation and analysis Abstract Circulating cell-free DNA (cfdna) has been shown
More informationSection D: The Molecular Biology of Cancer
CHAPTER 19 THE ORGANIZATION AND CONTROL OF EUKARYOTIC GENOMES Section D: The Molecular Biology of Cancer 1. Cancer results from genetic changes that affect the cell cycle 2. Oncogene proteins and faulty
More informationCharacterisation of structural variation in breast. cancer genomes using paired-end sequencing on. the Illumina Genome Analyser
Characterisation of structural variation in breast cancer genomes using paired-end sequencing on the Illumina Genome Analyser Phil Stephens Cancer Genome Project Why is it important to study cancer? Why
More informationIntro to Cancer Therapeutics
An Intro to Cancer Therapeutics Christopher R. Chitambar, MD Professor of Medicine Division of Hematology & Oncology Froedtert and Medical College of Wisconsin Clinical Cancer Center cchitamb@mcw.edu Intro
More informationDNA-seq Bioinformatics Analysis: Copy Number Variation
DNA-seq Bioinformatics Analysis: Copy Number Variation Elodie Girard elodie.girard@curie.fr U900 institut Curie, INSERM, Mines ParisTech, PSL Research University Paris, France NGS Applications 5C HiC DNA-seq
More informationThor Nilsen NeoGeneStar LLC January 22, 2015
Thor Nilsen NeoGeneStar LLC January 22, 2015 NeoGeneStar TM I. Liquid biopsy using circulating cell-free DNA: Cancer diagnostics Prenatal diagnostics Other disease states II. NeoGeneStar TM cell-free DNA
More informationBIT 120. Copy of Cancer/HIV Lecture
BIT 120 Copy of Cancer/HIV Lecture Cancer DEFINITION Any abnormal growth of cells that has malignant potential i.e.. Leukemia Uncontrolled mitosis in WBC Genetic disease caused by an accumulation of mutations
More informationThe Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer
The Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer Laura Spring, MD Breast Medical Oncology Massachusetts General Hospital Primary Mentor: Dr. Aditya Bardia
More informationBladder Cancer: Long-Term Survival With Metastatic Disease Case Reports and Review of the Literature. William Julian, MD. James J.
Bladder Cancer: Long-Term Survival With Metastatic Disease Case Reports and Review of the Literature William Julian, MD James J. Stark, MD, FACP Maryview Medical Center February 20, 2009 Dr. Julian to
More informationAn ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage Aaron M Newman1,2,7, Scott V Bratman1,3,7, Jacqueline To3, Jacob F Wynne3, Neville C W Eclov3, Leslie A Modlin3,
More informationPRECISION INSIGHTS. GPS Cancer. Molecular Insights You Can Rely On. Tumor-normal sequencing of DNA + RNA expression.
PRECISION INSIGHTS GPS Cancer Molecular Insights You Can Rely On Tumor-normal sequencing of DNA + RNA expression www.nanthealth.com Cancer Care is Evolving Oncologists use all the information available
More informationEducator Navigation Guide
Decoding Breast Cancer Virtual Lab Educator Navigation Guide Decoding Cancer Nav Guide 2 Introduction In this virtual lab, students test tissue samples from different patients with breast cancer in order
More informationNGS in Cancer Pathology After the Microscope: From Nucleic Acid to Interpretation
NGS in Cancer Pathology After the Microscope: From Nucleic Acid to Interpretation Michael R. Rossi, PhD, FACMG Assistant Professor Division of Cancer Biology, Department of Radiation Oncology Department
More informationSupplementary Tables. Supplementary Figures
Supplementary Files for Zehir, Benayed et al. Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients Supplementary Tables Supplementary Table 1: Sample
More informationTransforming Oncology With Precision Medicine Solutions. Company Overview January 2017
Transforming Oncology With Precision Medicine Solutions Company Overview January 2017 FORWARD-LOOKING STATEMENTS Statements in this presentation about the Company's expectations, applications of its technology,
More informationHands-On Ten The BRCA1 Gene and Protein
Hands-On Ten The BRCA1 Gene and Protein Objective: To review transcription, translation, reading frames, mutations, and reading files from GenBank, and to review some of the bioinformatics tools, such
More informationNCRI Biomarkers & Imaging CSG Cell-free DNA workshop
NCRI Biomarkers & Imaging CSG Cell-free DNA workshop Workshop Report Christie Education Centre, Manchester 30th January 2014 Sponsored by Workshop summary 86 delegates from a variety of specialities attended
More informationManagement of colorectal cancer liver metastases
Management of colorectal cancer liver metastases Aliakbarian M. M.D. Assistant professor of surgery Organ Transplant & Hepatopancreatobiliary Surgeon SUBJECTS The importance of surgical resection in colorectal
More informationYoungnam Cho. National Cancer Center Biomarker Branch
Youngnam Cho National Cancer Center Biomarker Branch Contents 1. Liquid Biopsy 2. Circulating Tumor Cells from Blood 3. Cell-free DNA from Blood 1. Liquid biopsy Cancer Diagnosis IMAGING TISSUE BIOPSY
More informationPatterns of Single-Gene Inheritance Cont.
Genetic Basis of Disease Patterns of Single-Gene Inheritance Cont. Traditional Mechanisms Chromosomal disorders Single-gene gene disorders Polygenic/multifactorial disorders Novel mechanisms Imprinting
More informationProducts for cfdna and mirna isolation. Subhead Circulating Cover nucleic acids from plasma
MACHEREY-NAGEL Products for cfdna and mirna isolation Bioanalysis Subhead Circulating Cover nucleic acids from plasma n Flexible solutions for small and large blood plasma volumes n Highly efficient recovery
More informationGenetic alterations of histone lysine methyltransferases and their significance in breast cancer
Genetic alterations of histone lysine methyltransferases and their significance in breast cancer Supplementary Materials and Methods Phylogenetic tree of the HMT superfamily The phylogeny outlined in the
More informationEvaluation of MIA FORA NGS HLA test and software. Lisa Creary, PhD Department of Pathology Stanford Blood Center Research & Development Group
Evaluation of MIA FORA NGS HLA test and software Lisa Creary, PhD Department of Pathology Stanford Blood Center Research & Development Group Disclosure Alpha and Beta Studies Sirona Genomics Reagents,
More information2/10/2016. Evaluation of MIA FORA NGS HLA test and software. Disclosure. NGS-HLA typing requirements for the Stanford Blood Center
Evaluation of MIA FORA NGS HLA test and software Lisa Creary, PhD Department of Pathology Stanford Blood Center Research & Development Group Disclosure Alpha and Beta Studies Sirona Genomics Reagents,
More informationEvolution of Breast Surgery
Evolution of Breast Surgery Natasha Rueth MD Surgical Oncologist Piper Breast Center and Alina Health Surgical Specialists Minneapolis, MN Definitions Radical Mastectomy: Removal of breast, chest muscles,
More informationNon-Mendelian inheritance
Non-Mendelian inheritance Focus on Human Disorders Peter K. Rogan, Ph.D. Laboratory of Human Molecular Genetics Children s Mercy Hospital Schools of Medicine & Computer Science and Engineering University
More informationBY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY
BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Cancer is a group of more than 100 different diseases that are characterized by uncontrolled cellular growth,
More informationTD* (n=46) Supplementary Table 2 Clinical characteristics of CHARGE participants with autism and typical development. Samples for mtdna deletions
1 Supplementary Material Supplementary Table1 Demographic characteristics of CHARGE participants with autism and typical development Samples for mtdna deletions Samples for mtdna sequencing (n=67) (n=46)
More informationIntroduction to Cancer Bioinformatics and cancer biology. Anthony Gitter Cancer Bioinformatics (BMI 826/CS 838) January 20, 2015
Introduction to Cancer Bioinformatics and cancer biology Anthony Gitter Cancer Bioinformatics (BMI 826/CS 838) January 20, 2015 Why cancer bioinformatics? Devastating disease, no cure on the horizon Major
More informationccfdna Webinar Series: The Basics and Beyond
ccfdna Webinar Series: The Basics and Beyond Part I Maxwell RSC ccfdna Plasma Kit and Maxwell RSC instrument are For Research Use Only. Not for Use in Diagnostic Procedures. Introduction to Circulating,
More information1. A method of selecting a treatment for congestive heart failure, in a subject with heart failure, comprising:
Diagnostic Methods Case Studies Instructions 1. Perform a Purposive Construction (PCon) of the claims: a. Identify the POSITA b. Identify the POSITA s CGK (in case study 2 this information has been specified
More informationWhen is Chemotherapy indicated in Advanced Luminal Breast Cancer?
When is Chemotherapy indicated in Advanced Luminal Breast Cancer? Soo-Chin Lee Head & Senior Consultant Department of Haematology-Oncology Clinical Care National University Cancer Institute, Singapore
More informationStructural Variation and Medical Genomics
Structural Variation and Medical Genomics Andrew King Department of Biomedical Informatics July 8, 2014 You already know about small scale genetic mutations Single nucleotide polymorphism (SNPs) Deletions,
More information7th November, Translational Science: how to move from biology to clinical applications
7th November, 2014 Translational Science: how to move from biology to clinical applications 1 Translational science: How to move from biology to clinical applications Translational cancer genomics and
More informationChIP-seq data analysis
ChIP-seq data analysis Harri Lähdesmäki Department of Computer Science Aalto University November 24, 2017 Contents Background ChIP-seq protocol ChIP-seq data analysis Transcriptional regulation Transcriptional
More informationMRC-Holland MLPA. Description version 29;
SALSA MLPA KIT P003-B1 MLH1/MSH2 Lot 1209, 0109. As compared to the previous lots 0307 and 1006, one MLH1 probe (exon 19) and four MSH2 probes have been replaced. In addition, one extra MSH2 exon 1 probe,
More informationContemporary Classification of Breast Cancer
Contemporary Classification of Breast Cancer Laura C. Collins, M.D. Vice Chair of Anatomic Pathology Professor of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA Outline
More informationThe Biology and Genetics of Cells and Organisms The Biology of Cancer
The Biology and Genetics of Cells and Organisms The Biology of Cancer Mendel and Genetics How many distinct genes are present in the genomes of mammals? - 21,000 for human. - Genetic information is carried
More informationAbstract. Optimization strategy of Copy Number Variant calling using Multiplicom solutions APPLICATION NOTE. Introduction
Optimization strategy of Copy Number Variant calling using Multiplicom solutions Michael Vyverman, PhD; Laura Standaert, PhD and Wouter Bossuyt, PhD Abstract Copy number variations (CNVs) represent a significant
More informationCancer Gene Panels. Dr. Andreas Scherer. Dr. Andreas Scherer President and CEO Golden Helix, Inc. Twitter: andreasscherer
Cancer Gene Panels Dr. Andreas Scherer Dr. Andreas Scherer President and CEO Golden Helix, Inc. scherer@goldenhelix.com Twitter: andreasscherer About Golden Helix - Founded in 1998 - Main outside investor:
More informationMultistep nature of cancer development. Cancer genes
Multistep nature of cancer development Phenotypic progression loss of control over cell growth/death (neoplasm) invasiveness (carcinoma) distal spread (metastatic tumor) Genetic progression multiple genetic
More informationImportance of Methodology Certification and Accreditations to Perform Assays. Stan Hamilton, MD Head, Pathology and Laboratory Medicine
Importance of Methodology Certification and Accreditations to Perform Assays Stan Hamilton, MD Head, Pathology and Laboratory Medicine 1 Disclosures No disclosures relevant to this presentation 2 A bad
More informationBreast Cancer. Excess Estrogen Exposure. Alcohol use + Pytoestrogens? Abortion. Infertility treatment?
Breast Cancer Breast Cancer Excess Estrogen Exposure Nulliparity or late pregnancy + Early menarche + Late menopause + Cystic ovarian disease + External estrogens exposure + Breast Cancer Excess Estrogen
More informationunderlying metastasis and recurrence in HNSCC, we analyzed two groups of patients. The
Supplementary Figures Figure S1. Patient cohorts and study design. To define and interrogate the genetic alterations underlying metastasis and recurrence in HNSCC, we analyzed two groups of patients. The
More informationPrevalence of HPV-16 genomic variant carrying a 63-bp duplicated sequence within the E1 gene in Slovenian women
Prevalence of HPV-16 genomic variant carrying a 63-bp duplicated sequence within the E1 gene in Slovenian women K E Y WORDS HPV-16, cervical cancer, E6-T350G variant A BSTRACT High-risk HPV, particularly
More informationAdvance Your Genomic Research Using Targeted Resequencing with SeqCap EZ Library
Advance Your Genomic Research Using Targeted Resequencing with SeqCap EZ Library Marilou Wijdicks International Product Manager Research For Life Science Research Only. Not for Use in Diagnostic Procedures.
More informationLiquid Biopsy. Jesus Garcia-Foncillas MD PhD. Director
Liquid Biopsy Jesus Garcia-Foncillas MD PhD Director Main issues about liquid biopsies New paradigm: Precision Medicine Heterogeneity & Dynamics Surrogate mirror for the tumor CTCs in colon cancer ctdna:
More informationAcute: Symptoms that start and worsen quickly but do not last over a long period of time.
Cancer Glossary Acute: Symptoms that start and worsen quickly but do not last over a long period of time. Adjuvant therapy: Treatment given after the main treatment. It usually refers to chemotherapy,
More informationPREVENTION OF HAEMOGLOBINOPATHIES: New methodologies and procedures Non-invasive Prenatal Diagnosis
PREVENTION OF HAEMOGLOBINOPATHIES: New methodologies and procedures Non-invasive Prenatal Diagnosis Marina Kleanthous Cyprus School of Molecular Medicine The Cyprus Institute of Neurology and Genetics
More informationDevelopment of Carcinoma Pathways
The Construction of Genetic Pathway to Colorectal Cancer Moriah Wright, MD Clinical Fellow in Colorectal Surgery Creighton University School of Medicine Management of Colon and Diseases February 23, 2019
More informationBiomarker for Response and Resistance in Ovarian Cancer
2016 대한부인종양학회제 31 차춘계학술대회 New Trends in Translational Research Biomarker for Response and Resistance in Ovarian Cancer Shin-Wha Lee, M.D., Ph.D. Department of Obstetrics and Gynecology ASAN Medical Center
More informationBreast Cancer: Who Gets It? Who Survives? The Latest Information
Breast Cancer: Who Gets It? Who Survives? The Latest Information James J. Stark, MD, FACP Medical Director, Cancer Program and Director of Palliative Care Maryview Medical Center Professor of Medicine
More informationmaintrac What's the future in precision diagnostics? From screening to stem cells and back!
maintrac What's the future in precision diagnostics? From screening to stem cells and back! Cancer is a frightening diagnosis: why? Malignant tumours are detectable when they have reached a size of about
More informationNational Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2011 Formula Grant
National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2011 Formula Grant Reporting Period July 1, 2012 June 30, 2013 Formula Grant Overview The NSABP Foundation
More informationUrinary ctdna Platform for Diagnosis and Cancer Treatment Monitoring. Summit August 19,2015
Urinary ctdna Platform for Diagnosis and Cancer Treatment Monitoring Mark G. Erlander, Ph.D., CSO CHI Next Generation Summit August 19,2015 Circulating Tumor DNA (ctdna) Tumor cells Main Advantages of
More informationFAQs for UK Pathology Departments
FAQs for UK Pathology Departments This is an educational piece written for Healthcare Professionals FAQs for UK Pathology Departments If you would like to discuss any of the listed FAQs further, or have
More informationCancer Genetics. What is Cancer? Cancer Classification. Medical Genetics. Uncontrolled growth of cells. Not all tumors are cancerous
Session8 Medical Genetics Cancer Genetics J avad Jamshidi F a s a U n i v e r s i t y o f M e d i c a l S c i e n c e s, N o v e m b e r 2 0 1 7 What is Cancer? Uncontrolled growth of cells Not all tumors
More informationIntegrated platform for liquid biopsy-based personalized cancer medicine
Integrated platform for liquid biopsy-based personalized cancer medicine Dr. Bernhard Polzer Fraunhofer ITEM-Regensburg Personalized Tumor Therapy Personalized cancer therapy Primary tumor single tumor
More informationMultigene Testing in NCCN Breast Cancer Treatment Guidelines, v1.2011
Multigene Testing in NCCN Breast Cancer Treatment Guidelines, v1.2011 Robert W. Carlson, M.D. Professor of Medicine Stanford University Chair, NCCN Breast Cancer Treatment Guidelines Panel Selection of
More informationAndreas Wicki. University Hospital Basel Switzerland
Andreas Wicki University Hospital Basel Switzerland Disclosures Funding of research projects: Piqur Therapeutics Consultancy: Actelion Pharmaceuticals Predictive Biomarkers for Targeted Therapy in Oncology
More informationNew Visions in PET: Surgical Decision Making and PET/CT
New Visions in PET: Surgical Decision Making and PET/CT Stanley J. Goldsmith, MD Director, Nuclear Medicine Professor, Radiology & Medicine New York Presbyterian Hospital- Weill Cornell Medical Center
More informationFONS Nové sekvenační technologie vklinickédiagnostice?
FONS 2010 Nové sekvenační technologie vklinickédiagnostice? Sekvenování amplikonů Sequence capture Celogenomové sekvenování FONS 2010 Sekvenování amplikonů Amplicon sequencing - amplicon sequencing enables
More information2016 CANCER PROGRAM REPORT. Bay Medical Sacred Heart Health System 615 North Bonita Avenue Panama City, FL
2016 CANCER PROGRAM REPORT Bay Medical Sacred Heart Health System 615 North Bonita Avenue Panama City, FL 32401 850.769.1511 www.baymedical.org 2016 Cancer Program Report Bay Medical Sacred Heart provides
More informationRecent advances in breast cancers
Recent advances in breast cancers Breast cancer is a hetrogenous disease due to distinct genetic alterations. Similar morphological subtypes show variation in clinical behaviour especially in response
More informationDisruptive innovation in molecular diagnostics. Hilde Windels CEO Biocartis 25 March 2017
Disruptive innovation in molecular diagnostics Hilde Windels CEO Biocartis 25 March 2017 1 One of the key innovations in healthcare in the last decade PERSONALISED MEDICINE or HIGH PRECISION MEDICINE From
More informationLESSON 3.2 WORKBOOK. How do normal cells become cancer cells? Workbook Lesson 3.2
For a complete list of defined terms, see the Glossary. Transformation the process by which a cell acquires characteristics of a tumor cell. LESSON 3.2 WORKBOOK How do normal cells become cancer cells?
More informationLiquid biopsy in lung cancer: The EGFR paradigm
Liquid biopsy in lung cancer: The EGFR paradigm Lynette M. Sholl, M.D. Brigham and Women s Hospital Dana Farber Cancer Institute Department of Pathology Boston, MA Disclosure of Relevant Financial Relationships
More informationMapping by recurrence and modelling the mutation rate
Mapping by recurrence and modelling the mutation rate Shamil Sunyaev Broad Institute of M.I.T. and Harvard Current knowledge is from Comparative genomics Experimental systems: yeast reporter assays Potential
More informationCURRENT GENETIC TESTING TOOLS IN NEONATAL MEDICINE. Dr. Bahar Naghavi
2 CURRENT GENETIC TESTING TOOLS IN NEONATAL MEDICINE Dr. Bahar Naghavi Assistant professor of Basic Science Department, Shahid Beheshti University of Medical Sciences, Tehran,Iran 3 Introduction Over 4000
More informationReporting TP53 gene analysis results in CLL
Reporting TP53 gene analysis results in CLL Mutations in TP53 - From discovery to clinical practice in CLL Discovery Validation Clinical practice Variant diversity *Leroy at al, Cancer Research Review
More informationSurgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14
Surgical Management of Advanced Stage Colon Cancer Nathan Huber, MD 6/11/14 Colon Cancer Overview Approximately 50,000 attributable deaths per year Colorectal cancer is the 3 rd most common cause of cancer-related
More informationCELL BIOLOGY - CLUTCH CH CANCER.
!! www.clutchprep.com CONCEPT: OVERVIEW OF CANCER Cancer is a disease which is primarily caused from misregulated cell division, which form There are two types of tumors - Benign tumors remain confined
More informationColorectal Cancer at the MemorialCare Todd Cancer Institute at Long Beach Memorial
Colorectal Cancer at the MemorialCare Todd Cancer Institute at Long Beach Memorial ANNUAL REPOR T (562) 933-0900 MemorialCare.org/TCI 2810 Long Beach Blvd. Long Beach, CA 90806 #3 Colorectal cancer is
More informationINDIVIDUALIZED MEDICINE
CENTER FOR INDIVIDUALIZED MEDICINE Precision Oncology: Current Applications of omics ACP Arizona Chapter Scientific Meeting, 2014 Arizona State University in Tempe, Arizona Alan Bryce, MD 2012 MFMER slide-1
More information